Lexicon Pharmaceuticals
Market Cap
US$157.4m
Last Updated
2020/10/19 06:03 UTC
Data Sources
Company Financials +
Executive Summary
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products. More Details
Rewards
Risk Analysis
Snowflake Analysis
Undervalued with questionable track record.
Similar Companies
Share Price & News
How has Lexicon Pharmaceuticals's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: LXRX's share price has been volatile over the past 3 months.
Market Performance
7 Day Return
-1.3%
LXRX
-3.4%
US Biotechs
-2.4%
US Market
1 Year Return
-55.5%
LXRX
35.9%
US Biotechs
18.2%
US Market
Return vs Industry: LXRX underperformed the US Biotechs industry which returned 40.2% over the past year.
Return vs Market: LXRX underperformed the US Market which returned 19.9% over the past year.
Shareholder returns
| LXRX | Industry | Market | |
|---|---|---|---|
| 7 Day | -1.3% | -3.4% | -2.4% |
| 30 Day | -9.3% | 0.7% | 4.2% |
| 90 Day | -29.2% | -4.7% | 6.3% |
| 1 Year | -55.5%-55.5% | 38.3%35.9% | 20.9%18.2% |
| 3 Year | -86.5%-86.5% | 18.5%12.5% | 41.2%31.8% |
| 5 Year | -86.3%-86.3% | 17.2%8.9% | 84.8%63.9% |
Price Volatility Vs. Market
How volatile is Lexicon Pharmaceuticals's share price compared to the market and industry in the last 5 years?
Simply Wall St News
3 weeks ago | Simply Wall St
Need To Know: Analysts Are Much More Bullish On Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Revenues1 month ago | Simply Wall St
A Quick Analysis On Lexicon Pharmaceuticals' (NASDAQ:LXRX) CEO Compensation2 months ago | Simply Wall St
Analysts Just Made A Major Revision To Their Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Revenue ForecastsValuation
Is Lexicon Pharmaceuticals undervalued compared to its fair value and its price relative to the market?
>50%
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: LXRX ($1.47) is trading below our estimate of fair value ($47.08)
Significantly Below Fair Value: LXRX is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: LXRX is good value based on its PE Ratio (4x) compared to the US Biotechs industry average (27.2x).
PE vs Market: LXRX is good value based on its PE Ratio (4x) compared to the US market (19x).
Price to Earnings Growth Ratio
PEG Ratio: LXRX is good value based on its PEG Ratio (0.7x)
Price to Book Ratio
PB vs Industry: LXRX has negative assets, so we can't compare its PB Ratio to the US Biotechs industry average.
Next Steps
Future Growth
How is Lexicon Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?
5.5%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: LXRX's forecast earnings growth (5.5% per year) is above the savings rate (2.2%).
Earnings vs Market: LXRX's earnings (5.5% per year) are forecast to grow slower than the US market (22.1% per year).
High Growth Earnings: LXRX's earnings are forecast to grow, but not significantly.
Revenue vs Market: LXRX's revenue is expected to decline over the next 3 years (-28.1% per year).
High Growth Revenue: LXRX's revenue is forecast to decline over the next 3 years (-28.1% per year).
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: LXRX is forecast to be unprofitable in 3 years.
Next Steps
Past Performance
How has Lexicon Pharmaceuticals performed over the past 5 years?
24.8%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: LXRX has a large one-off loss of $30.2M impacting its June 30 2020 financial results.
Growing Profit Margin: LXRX became profitable in the past.
Past Earnings Growth Analysis
Earnings Trend: LXRX has become profitable over the past 5 years, growing earnings by 24.8% per year.
Accelerating Growth: LXRX has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: LXRX has become profitable in the last year, making it difficult to compare its past year earnings growth to the Biotechs industry (-3.2%).
Return on Equity
High ROE: LXRX's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.
Next Steps
Financial Health
How is Lexicon Pharmaceuticals's financial position?
Financial Position Analysis
Short Term Liabilities: LXRX has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.
Long Term Liabilities: LXRX has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.
Debt to Equity History and Analysis
Debt Level: LXRX has negative shareholder equity, which is a more serious situation than a high debt level.
Reducing Debt: LXRX's has negative shareholder equity, so we do not need to check if its debt has reduced over time.
Debt Coverage: LXRX's debt is well covered by operating cash flow (39.9%).
Interest Coverage: LXRX's interest payments on its debt are well covered by EBIT (4.7x coverage).
Balance Sheet
Next Steps
Dividend
What is Lexicon Pharmaceuticals's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate LXRX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate LXRX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if LXRX's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if LXRX's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of LXRX's dividend in 3 years as they are not forecast to pay a notable one for the US market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
11.7yrs
Average management tenure
CEO
Lonnel Coats (55 yo)
6.25yrs
Tenure
US$3,870,291
Compensation
Mr. Lonnel Coats has been the Chief Executive Officer and President of Lexicon Pharmaceuticals, Inc., since July 7, 2014. Mr. Coats served as an Executive Vice President, President of Americas Region at Ei ...
CEO Compensation Analysis
Compensation vs Market: Lonnel's total compensation ($USD3.87M) is above average for companies of similar size in the US market ($USD1.27M).
Compensation vs Earnings: Lonnel's compensation has been consistent with company performance over the past year.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 6.25yrs | US$3.87m | 0.28% $ 439.3k | |
| Executive VP of Corporate & Administrative Affairs and CFO | 10.42yrs | US$1.61m | 0.11% $ 169.8k | |
| Executive Vice President of Research & Development | 4.42yrs | US$1.68m | 0.065% $ 101.9k | |
| Consultant & Independent Director | 19.67yrs | US$88.76k | 0.015% $ 24.1k | |
| Vice President of Finance & Accounting | 12.92yrs | US$508.34k | 0.061% $ 95.7k | |
| Head of Investor Relations & Corporate Strategy | no data | no data | no data | |
| VP, General Counsel & Secretary | 10.42yrs | no data | 0.046% $ 73.1k | |
| Executive Director of Corporate Communications & Patient Advocacy | 19.75yrs | no data | no data | |
| Executive Vice President of Commercial Supply Operations | 19.25yrs | no data | 0.098% $ 153.8k |
11.7yrs
Average Tenure
60yo
Average Age
Experienced Management: LXRX's management team is seasoned and experienced (11.7 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 6.25yrs | US$3.87m | 0.28% $ 439.3k | |
| Consultant & Independent Director | 19.67yrs | US$88.76k | 0.015% $ 24.1k | |
| Independent Chairman of the Board | 8.67yrs | US$118.18k | 0.30% $ 465.8k | |
| Independent Director | 20.58yrs | US$107.18k | 0.052% $ 81.8k | |
| Independent Director | 13.17yrs | US$90.96k | 0.015% $ 24.1k | |
| Independent Director | 13.17yrs | US$84.55k | 0.13% $ 206.9k | |
| Independent Director | 13.08yrs | US$96.87k | 0.015% $ 24.1k | |
| Chairman of Medical Advisory Board & Independent Director | 17.58yrs | US$84.55k | 0.016% $ 25.1k | |
| Independent Director | 15.92yrs | US$105.98k | 0.015% $ 24.1k |
13.2yrs
Average Tenure
65yo
Average Age
Experienced Board: LXRX's board of directors are seasoned and experienced ( 13.2 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
Lexicon Pharmaceuticals, Inc.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: Lexicon Pharmaceuticals, Inc.
- Ticker: LXRX
- Exchange: NasdaqGS
- Founded: 1995
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$157.446m
- Shares outstanding: 107.11m
- Website: https://www.lexpharma.com
Number of Employees
Location
- Lexicon Pharmaceuticals, Inc.
- 8800 Technology Forest Place
- The Woodlands
- Texas
- 77381-1160
- United States
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| LXRX | NasdaqGS (Nasdaq Global Select) | Yes | Common Shares | US | USD | Apr 2000 |
| LX31 | DB (Deutsche Boerse AG) | Yes | Common Shares | DE | EUR | Apr 2000 |
| LX31 | MUN (Boerse Muenchen) | Yes | Common Shares | DE | EUR | Apr 2000 |
Biography
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products. The company offers XERMELO, an orally-delivered small molecule drug ...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2020/10/19 06:03 |
| End of Day Share Price | 2020/10/16 00:00 |
| Earnings | 2020/06/30 |
| Annual Earnings | 2019/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.